147 related articles for article (PubMed ID: 37160416)
41. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.
Lim K; Han C; Dai Y; Shen M; Wu T
Mol Cancer Ther; 2009 Nov; 8(11):3046-55. PubMed ID: 19887546
[TBL] [Abstract][Full Text] [Related]
42. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
43. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
[TBL] [Abstract][Full Text] [Related]
44. Aquaporin 9 inhibits growth and metastasis of hepatocellular carcinoma cells via Wnt/β-catenin pathway.
Liao S; Chen H; Liu M; Gan L; Li C; Zhang W; Lv L; Mei Z
Aging (Albany NY); 2020 Jan; 12(2):1527-1544. PubMed ID: 31969493
[TBL] [Abstract][Full Text] [Related]
45. Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis.
Yang Z; Liu J; Xue F; Zhang L; Xue H; Wu Y; Bai S; Du F; Wang X; Deng W; Song C; Wang K
Ann Hepatol; 2023; 28(2):100898. PubMed ID: 36634747
[TBL] [Abstract][Full Text] [Related]
46. Crosstalk between liver-related microRNAs and Wnt/β-catenin pathway in hepatocellular carcinoma patients.
Ashmawy AM; Elgeshy KM; Abdel Salam ET; Ghareeb M; Kobaisi MH; Amin HAA; Sharawy SK; Abdel Wahab AHA
Arab J Gastroenterol; 2017 Sep; 18(3):144-150. PubMed ID: 28958640
[TBL] [Abstract][Full Text] [Related]
47. Small Cell Lung Carcinoma with Pancoast Syndrome: A Case Report.
Limbu SH; Bhatta N; Mishra DR; Acharya AB; Verma A; Shahi R; Katuwal S; Singh SK
JNMA J Nepal Med Assoc; 2022 Feb; 60(246):211-213. PubMed ID: 35210644
[TBL] [Abstract][Full Text] [Related]
48. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
[TBL] [Abstract][Full Text] [Related]
49. The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
Krug S; Mattheis L; Haemmerle M; Rosendahl J; Kleeff J; Michl P
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1493. PubMed ID: 34309225
[TBL] [Abstract][Full Text] [Related]
50. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
51. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling.
Quan H; Li B; Yang J
Biomed Pharmacother; 2018 Nov; 107():754-762. PubMed ID: 30142536
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation.
Kuwano A; Yada M; Narutomi F; Nagasawa S; Tanaka K; Kurosaka K; Ohishi Y; Masumoto A; Motomura K
Oncol Lett; 2022 Jul; 24(1):216. PubMed ID: 35720502
[TBL] [Abstract][Full Text] [Related]
53. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma.
Yang XD; Kong FE; Qi L; Lin JX; Yan Q; Loong JHC; Xi SY; Zhao Y; Zhang Y; Yuan YF; Ma NF; Ma S; Guan XY; Liu M
Mol Cancer; 2021 Jan; 20(1):20. PubMed ID: 33485358
[TBL] [Abstract][Full Text] [Related]
54. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
55. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
56. Solitary nasopharynx metastasis from hepatocellular carcinoma after liver transplantation: A case report.
Lou LL; Zhang Y; Huang X; Zhang LX; Ji HF; Li X; Guo XL
Medicine (Baltimore); 2019 Feb; 98(7):e14368. PubMed ID: 30762736
[TBL] [Abstract][Full Text] [Related]
57. Dimeric oxyberberine CT4-1 targets LINC02331 to induce cytotoxicity and inhibit chemoresistance via suppressing Wnt/β-catenin signaling in hepatocellular carcinoma.
Lin X; Chen J; Li X; Chen D; Luo K; Deng Y; Yang D; Huang Z; Tao C
Arch Toxicol; 2023 Jun; 97(6):1627-1647. PubMed ID: 37120773
[TBL] [Abstract][Full Text] [Related]
58. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation.
Haines K; Sarabia SF; Alvarez KR; Tomlinson G; Vasudevan SA; Heczey AA; Roy A; Finegold MJ; Parsons DW; Plon SE; López-Terrada D
Pediatr Blood Cancer; 2019 Jul; 66(7):e27745. PubMed ID: 30977242
[TBL] [Abstract][Full Text] [Related]
59. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
Sugimoto R; Satoh T; Ueda A; Senju T; Tanaka Y; Yamashita S; Koyanagi T; Kurashige T; Higuchi N; Nakamura T; Tanaka M; Azuma Y; Ohno A; Ooho A; Ooe M; Mutsuki T; Uchimura K; Kuniyoshi M; Tada S; Aratake Y; Yoshimoto T; Yamashita N; Harada S; Nakamuta M; Motomura K; Kohjima M;
Medicine (Baltimore); 2022 Oct; 101(40):e30871. PubMed ID: 36221372
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA-639 is Down-Regulated in Hepatocellular Carcinoma Tumor Tissue and Inhibits Proliferation and Migration of Human Hepatocellular Carcinoma Cells Through the KAT7/Wnt/β-Catenin Pathway.
Bai Z; Xia X; Lu J
Med Sci Monit; 2020 Jan; 26():e919241. PubMed ID: 31955177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
